Have Skyrizi and Rinvoq Successfully Saved AbbVie From Humira LoE?

  • ABBV eyes $24.7 billion from Skyrizi and Rinvoq in 2025 as ex-Humira growth offsets sharp sales drop post-U.S. patent loss.